Appointment of Non-Executive Director

For immediate release:

ValiRx appoints James Nicholas Thorniley as non-executive director

ValiRx plc (AIM: VAL) ("ValiRx" or the "Company"), the cancer therapeutics
company, today announces that it has appointed James Nicholas ("Nick")
Thorniley (age 62) to the Board as a non-executive director with immediate
effect.

Nick Thorniley's City career spans some 38 years. Latterly, he has concentrated
on corporate broking having been a director and head of corporate broking at
both Investec Securities (2002-2005) and, previously, at Panmure Gordon
(1990-2002).

Nick Thorniley currently holds 11,812,500 ordinary shares of 0.2p each in the
Company ("Ordinary Shares") representing 1.33% of the issued Ordinary Share
capital of the Company. In addition, he holds an entitlement to a further
3,150,000 Deferred Consideration Shares, details of which are included in the
Company's admission document dated 8 September 2006.

Anthony Moore, Chairman of ValiRx, commented:

"Nick has had an extensive career in corporate broking and played an
instrumental role in the Company's reverse takeover and admission to AIM. Going
forward, we believe he will be a valuable resource to the Board as we look to
target further acquisition and investment opportunities."

There is no further information to disclose under Schedule Two paragraph (g) of
the AIM Rules.

- ENDS -

Information on ValiRx plc

ValiRx is a biopharmaceutical development company that is building a portfolio
of complementary cancer-related therapeutic and diagnostic technologies. It
currently holds stakes in Cronos Therapeutics Limited and Morphogenesis Inc:

  * Cronos Therapeutics Limited holds licenses to two innovative and
    potentially market changing technologies, GeneICE and HyperGenomics. The
    Company has been informed by the European Patent Office that it is to
    receive the granting of a patent for its GeneICE cancer technology.
   
  * Morphogenesis Inc. is developing a portfolio of cell therapy products for
    the treatment of chronic disorders. Its most advanced product is ImmuneFxâ„¢
    for which it recently received a patent from the US patent office.
   
ValiRx is headquartered in London, England.


Contact Details:

     ValiRx plc          WH Ireland Limited          GTH Communications     
                                                                            
  Dr Satu Vainikka         David Youngman       Toby Hall / Jade Mamarbachi 
                                                                            
[phone]    [phone]    [phone] / 8035